Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Gastrointestinal 1Endocrine 1

Conditions

Leukemia, Myeloid, Acute 25Advanced Solid Tumors 18Breast Neoplasms 12Myelodysplastic Syndromes 11Neoplasms 10Advanced Solid Tumor 10Prostatic Neoplasms 9Solid Tumor 7Neoplasm Metastasis 7Multiple Myeloma 7Recurrence 6Carcinoma, Non-Small-Cell Lung 6Pancreatic Neoplasms 5Colorectal Neoplasms 5Stomach Neoplasms 4Small Cell Lung Carcinoma 4Melanoma 4Leukemia, Myelomonocytic, Chronic 4Leukemia 4Solid Tumors 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Ovarian Neoplasms 3Lung Neoplasms 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Primary Myelofibrosis 2Nasopharyngeal Carcinoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell 2

Interventions

radiprodil 2Sirolimus 2exemestane 1Melatonin 1Itraconazole 1Injections 1Everolimus 1Carbamazepine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Tuberous Sclerosis × Injections × Clear all
NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

SAPU NANO (US) LLC

Phase 1 Recruiting
27 enrolled
EndocrineGastrointestinalGenitourinaryNET

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡